Healthcare Company

Pro-GeneX, LLC

To find out if this company and others are accepting funding, .

Funding Goal
Funding Raised So Far
Funding Commitments
Funding Remaining
Funding Type
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


Pro-GeneX is a mature 10-year-old company with a national reputation for delivering molecular diagnostic testing coupled with industry-leading clinical decision support teams to providers seeking to improve patient outcomes and reduce costs of care.

Nearly 100,000 people die annually due to Adverse Drug Events/Adverse Drug Reactions. More than 1.5 million are hospitalized and the annual cost for treating these avoidable injuries exceeds $180 billion USD. The APA estimates that more than 10% of patients are taking at least one drug that isn’t working for them. The need exists to provide an immediate solution to the rising number of patient injuries. Long Term Care Operators and healthcare systems are under CMS mandates to improve in a large number of value-based care initiatives. To maximize revenues and minimize penalties it is also important to reduce the time required to bring patients to a high level of therapeutic benefit related to their medications.

OUR PRODUCT
One of our genetic test products evaluates liver-based metabolism of medications in the body. This process is called Pharmacogenetics (PGX). The test determines if the genes related to this system are causing the body to produce normal amounts of enzymes used in the metabolism of drugs. Mutations in this system are common, resulting in non-standard enzyme expression.
Pharmacogenetics is a proven technology, assisting physicians and patients in selecting the right medication and the right dosage level at the outset of treatment, minimizing the risk of adverse drug events (ADRs) and improving outcomes. By knowing an individual’s specific metabolism of medications, physicians can make adjustments to dosage early on, or even choose a different medication. The result is a reduction of costs and an increase in patient satisfaction which can help drive additional revenue. The tests have reimbursement from CMS and most private insurers.

We are the only company of our kind in the industry that provides census-level data from our testing results to healthcare networks, assisting in documenting positive change across important metrics and demonstrating meaningful use to drive larger reimbursement rates from CMS.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary


Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Products/Services


Pharmacogenetic Testing

Our genetic test products evaluate the Cytochrome P450 system in the body. This process is called Pharmacogenetic testing (PGX). The test determines if the genes related to this system are causing the body to express normal amounts of enzymes used in the metabolism of drugs. Abnormalities in this system are common, resulting in non-standard enzyme expression.
Pharmacogenetic testing holds the promise of assisting physicians and patients in selecting the right medication and the right dosage level at the outset of treatment, minimizing the risk of adverse drug events (ADRs) and maximizing outcomes. By knowing an individual’s specific metabolism of specific medications, physicians can make adjustments to dosage early on, or even choose a different medication.. The tests are FDA approved and have reimbursement from CMS and most private insurers. Our lab handles all billing so there is no added administrative burden to the client.

Molecular Diagnostics for infectious disease (2022)

With healthcare focused on precision medicine and more individualized treatments, the molecular diagnostics industry has grown over the last 10 years and today is poised to supplant many culture-based testing modalities. The differences between the methods are dramatic. Molecular processes allow for identification of specific pathogens 7 times faster than older methods that require the specimens to be cultured or grown in media over 25-30 hours. Culturing produces results with high levels of false positives and false negatives. Many of these also identify pathogens that have developed anti-biotic resistance markers. Having this information allows our teams of pharmacists to recommend targeted medication therapies and help physicians to avoid the use of broad-spectrum antibiotics. The use of this technology reduces cost of care, improves outcomes and shortens the time required to manage new pathogens that are sometimes fatal. Tests for UTI, VM, GI, wound care, Respiratory pathogens.

Management


Robert Rupard
Chief Executive Officer
Robert R......

Since 2014, he has been CEO and founder of Pro-GeneX Laboratories and Clinical Services. Today he is a nationally recognized thought leader and pioneer in the use of novel molecular diagnostic technologies to improve patient outcomes and decrease costs of care. From 2010 until early 2014 he served as Chief Operating Officer for Sensiotec, Inc., a Georgia Tech-based medical device firm.

Prior to that, he was Founder and Chief Executive Officer / Director of Operations for Wings Air, a 75-employee, commuter airline that provided commuter service in the SE U.S., provided scheduled service into Hartsfield Jackson International Airport. He was responsible for gate operations at Hartsfield Jackson Airport, successfully negotiating changes in the airport security plan and establishing a new record for regulatory approval and airline conversion in the commuter industry,

To find out if this company and others are accepting funding, .

Funding Goal
Funding Raised So Far
Funding Commitments
Funding Remaining
Funding Type
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


Pro-GeneX, LLC

Atlanta, GA 30308, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).